Nationwide Soap Recall Issued Over Contamination Linked to Sepsis
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
DermaRite Industries has voluntarily recalled specific lots of its products nationwide due to contamination with Burkholderia cepacia, a bacterium that can cause serious infections in immunocompromised individuals.
The products include DermaKleen, Dermasarra, Kleenfoam, and Perigiene items.
Newsweek contacted DermaRite Industries for comment via online form on Sunday.
Why It Matters
Burkholderia cepacia is a group of bacteria commonly found in soil and water. While it typically poses little risk to healthy individuals, it can lead to life-threatening infections, including sepsis, in those with weakened immune systems. The affected products were distributed across the United States and Puerto Rico.
Stock image of a person using a liquid soap dispenser.
Stock image of a person using a liquid soap dispenser.What To Know
The products are commonly used in health care settings for handwashing and skin care. The recalled products, as per the company recall notice, are:
Product Description Reorder # Lot Number Expiration Date DermaKleen 1000ml. bag-n-box, 10/case 0092BB 30586A 7/2025 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 30586B 7/2025 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 30626A 7/2025 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 30628A 8/2025 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 30657A 8/2025 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 30741A 7/2025 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 30871A 10/2025 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 40002A 12/2025 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 40012A 1/2026 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 40301A 3/2026 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 40789A 9/2026 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 50068B 1/2027 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 50144A 2/2027 DermaKleen 1000ml. bag-n-box, 10/case 0092BB 50149A 2/2027 DermaKleen 800ml. bag-n-box, 12/case 0090BB 30550A 7/2025 DermaKleen 800ml. bag-n-box, 12/case 0090BB 30670A 8/2025 DermaKleen 800ml. bag-n-box, 12/case 0090BB 30682A 8/2025 DermaKleen 800ml. bag-n-box, 12/case 0090BB 40025A 1/2026 DermaKleen 800ml. bag-n-box, 12/case 0090BB 40375A 4/2026 DermaKleen 800ml. bag-n-box, 12/case 0090BB 40427A 5/2026 DermaKleen 800ml. bag-n-box, 12/case 0090BB 40436A 5/2026 DermaKleen 800ml. bag-n-box, 12/case 0090BB 50068A 1/2027 DermaSarra 7.5oz, 24/case 00188 40187.2 2/2026 KleenFoam 1000ml., 6/case 0093F 30705A 8/2025 KleenFoam 1000ml., 6/case 0093F 30771A 9/2025 KleenFoam 1000ml., 6/case 0093F 30920A 10/2025 KleenFoam 1000ml., 6/case 0093F 40016A 1/2026 KleenFoam 1000ml., 6/case 0093F 40303A 4/2026 KleenFoam 1000ml., 6/case 0093F 40428A 5/2026 KleenFoam 1000ml., 6/case 0093F 40505A 6/2026 KleenFoam 1000ml., 6/case 0093F 41053C 12/2026 KleenFoam 1000ml., 6/case 0093F 41053A 12/2026 KleenFoam 1000ml., 6/case 0093F 41053B 12/2026 KleenFoam 1000ml., 6/case 0093F 50017A 1/2027 PeriGiene 7.5oz., 48/case 00198 31013A 11/2025 PeriGiene 7.5oz., 48/case 00198 40345A 4/2026 PeriGiene 7.5oz., 48/case 00198 40355A 4/2026 PeriGiene 7.5oz., 48/case 00198 40571A 6/2026 PeriGiene 7.5oz., 48/case 00198 40580A 6/2026 PeriGiene 7.5oz., 48/case 00198 40587A 7/2026 PeriGiene 7.5oz., 48/case 00198 40591A 7/2026 PeriGiene 7.5oz., 48/case 00198 40870.1 10/2026 PeriGiene 7.5oz., 48/case 00198 40877.1 10/2026 PeriGiene 7.5oz., 48/case 00198 41093A 12/2026 PeriGiene 7.5oz., 48/case 00198 50072A 1/2027 PeriGiene 7.5oz., 48/case 00198 50079A 1/2027
A full list of recalled products and product labels is also provided on the Food and Drug Administration's website here.
What People Are Saying
Recall notice risk statement on the DermaRite website: "Burkholderia cepacia complex in these products may result in serious and life-threatening infections. The contaminated products may be used by immunosuppressed individuals or by people attending to immunosuppressed individuals.
"In healthy individuals with minor skin lesions, the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into [the] blood stream leading to life-threatening sepsis. To date, DermaRite has not received any reports of adverse events related to this recall."
What Happens Next
Individuals using these products, especially those with compromised immune systems, should discontinue use immediately.
The company advises that consumers should contact their physician or health care provider if they have experienced any problems that may be related to using this product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.
Complete and submit the report online: www.fda.gov/medwatch/report.htm
Mail or fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Consumers with questions regarding this recall can call DermaRite on 973-569-9000 x104 Monday through Friday, 9 a.m.—5 p.m. ET, email voluntary.action@dermarite.com, or visit the official website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
18 minutes ago
- Newsweek
Gen Z and Millennials Have Differing Views on Ozempic
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Gen Z and millennials have radically different views on GLP-1s like Ozempic and how much they want the weight loss and diabetes drugs regulated, according to a new report from GLP-1 prescription weight loss company Levity. While 40 percent of current and recent GLP-1 (glucagon-like peptide-1) users said the current regulations are fair, 28 percent want fewer rules and 22 percent said there should be more. But in the millennial age group, users tend to want less regulation, while Gen Z leaned toward more. Why It Matters GLP-1s, which are injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity in recent years. Popular products, including Ozempic, Mounjaro, Wegovy and Zephound, have been a game changer for many Americans who are obese or have type 2 diabetes. However, stricter FDA rules are now in effect, banning certain compounded GLP-1s and making it more difficult for many Americans to secure the drugs, especially if using it for weight loss reasons. Ozempic is medicine for adults with type 2 diabetes. Ozempic is medicine for adults with type 2 diabetes. Steve Christo - Corbis/Corbis via Getty Images What To Know The Gen Z and millennial response to the stricter FDA rules have been notably different, according to Levity. At 31 percent, millennials were the most likely to favor fewer GLP-1 regulations compared to 19 percent of the group who wanted more. Gen Z, meanwhile, favored stricter rules at 37 percent, while 32 percent wanted fewer. "Millennials are more likely to be prescribed a GLP-1 as compared to Gen Z; therefore, it is not surprising that millennials desire less regulation on these drugs," Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek. "Having said that, the regulatory environment surrounding compounded agents, in general, and compounded GLP-1s, specifically, is not as rigorous as it is for branded and generic drugs. Therefore, compounded drugs carry unknown risks that more regulated medications do not." Because semaglutide is no longer on the FDA shortage list, compounding it can carry legal risks. Already, the effects are being felt, as 17 percent of GLP-1 users said it has become harder to get their medication since the FDA tightened rules on compounded semaglutide, Levity reported. There was also a difference in how the generations viewed their use of the drugs. While 75 percent of GLP-1 users believed they'll still be on their treatment plan a year from now, Gen Z was the least likely to think so, at 58 percent. What People Are Saying Board-certified endocrinologist Dr. Caroline Messer told Newsweek: "Millennials, many of whom are now managing midlife weight and metabolic health concerns, may see GLP-1s as a practical tool and want fewer barriers. Gen Z, meanwhile, is generally more wary of long-term unknowns, hence leaning toward more safeguards. Broadly, Americans are divided but lean toward keeping current regulations." Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek: "From a business perspective, limiting access to compounded drugs when branded drugs are available protects the drug companies' patents. This protection provides the financial incentive for drug companies to develop innovative new therapies." What Happens Next The long-term effects of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. And GLP-1 medications have also been associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea and even stomach paralysis in rare cases.
Newsweek
an hour ago
- Newsweek
Supreme Court Faces Decision on LGBTQ+ Conversion Therapy
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Supreme Court is preparing to hear arguments this fall in a case about whether it should uphold or overturn Colorado's ban on LGBTQ+ conversion therapy. Why It Matters More than 20 states have banned conversion therapy, the practice of trying to change a person's sexual orientation or gender identity through counseling. The practice has drawn scrutiny from LGBTQ+ advocates and many medical professionals who say conversion therapy does not work, lacks a scientific basis and can impose harm on minors. The nation's highest court on Tuesday announced that it will hear arguments in the case Chiles v. Salazar on October 7, 2025. The ruling could have key implications for the legality of conversion therapy in the states that have banned the practice. It has drawn concerns within the community, as some are concerned that the conservative-leaning bench could require states to allow conversion therapy. What To Know The Supreme Court case focuses on Kaley Chiles, a counselor in Colorado who challenged the state's law prohibiting the use of conversion therapy on minors. In a petition to the Supreme Court, her attorneys wrote that she is a "licensed counselor who helps people by talking with them." The petition raised a First Amendment argument, accusing Colorado of trying to ban "consensual conversations based on the viewpoints they express." Proponents of the ban on conversion therapy point to statistics showing it can harm LGBTQ+ youth. A 2020 study from the Trevor Project found that minors who underwent conversion therapy were more than twice as likely to have reported suicide attempts and more than 2.5 times as likely to report multiple suicide attempts compared to those who did not. Supporters argue that the state has the authority to regulate health care services that put minors at risk. Photo-illustration by Newsweek/Canva/Getty Colorado Attorney General Phil Weiser, a Democrat, argued in a filing that Court precedent "allows states to reasonably regulate professional conduct to protect patients from substandard treatment, even when that regulation incidentally burdens speech." "The Court of Appeals engaged in a straightforward application of this precedent to hold that the First Amendment allows states to regulate the professional practice of conversion therapy, like other unsafe and ineffective health care treatments, to protect minor patients from substandard professional care," he wrote. Former federal prosecutor Gene Rossi told Newsweek that the "Supreme Court's tea leaves seem to suggest that the Colorado law may be in peril." "That law proscribes alleged 'conversion therapy' by a professional counselor, whose sincere views are based on her Christian ideals and whose clients (adults and young people) actively seek her guidance because of their shared religious beliefs. To the Court, based on earlier cases, children are extremely vulnerable to the possible risks of such therapy and lack the maturity to accept or reject it," he said. However, the counselor argues that her First Amendment rights to "advise and assist her willing clients, who voluntarily wish to align their lives with their Christian faith, are unconstitutionally abridged by the broad state's law." "We shall see next year what the Court decides in this difficult case," Rossi said. Ryan Thoreson, a professor of law at the University of Cincinnati, told Newsweek he believes Colorado has strong arguments in favor of its ban, but that he is "skeptical this Court will uphold the state's conversion therapy ban in light of its recent First Amendment rulings." "The Roberts Court has been consistently solicitous toward free speech and religious exercise claims brought by conservative litigants, even when those claims undermine longstanding laws that protect LGBT people from discrimination and harm," he said. Colorado is likely to argue that it is "well-established that states can permissibly regulate the conduct of medical professionals, and can prohibit practices that fall below a certain standard of professional care." "And they can do so even when that conduct involves some amount of speech. While the state can't prevent private citizens from voicing their opinion that sexual orientation or gender identity can be changed, they can prevent licensed medical professionals from trying to promote or facilitate that change as part of their practice, especially in light of a large body of evidence showing that conversion therapy is damaging to young LGBT people's mental health," Thoreson said. Chiles, meanwhile, is likely to argue the law censors her speech based on her views about sexual orientation and gender identity. Generally, if the state is censoring speech based on content, it must pass a "heavy burden" to prove a "compelling interest in limiting the speech" and that the regulation is the least speech-restrictive way of achieving its interest, Thoreson said. Colorado likely would not be the only state affected, according to Thoreson. "What the Supreme Court decides in this case could also have seismic repercussions for state regulation of medical speech more generally. A broad First Amendment right of medical providers to say or recommend whatever they like without professional or legislative oversight, even when there is clear evidence that doing so is harmful, could open the door to pseudoscience and junk science in both medical and physical health care settings," he said. Jonathan Scruggs, senior counsel and vice president of litigation strategy at the Alliance Defending Freedom, which is representing Chiles, told Newsweek that children should not be "forced into one-size-fits-all options when they're looking for counseling help." "They deserve real support, not just state-approved talking points. Our client Kaley Chiles, a licensed counselor in Colorado, works with her clients who voluntarily come to her with their goals to talk through what they are facing. Struggling kids deserve better than Colorado's law that pushes them toward harmful drugs and surgeries," he said. Jennifer Levi, senior director of transgender and queer rights at GLAD Law, told Newsweek there is a "real risk that the outcome indeed may be here that the court strikes down a ban on conversion therapy for minors." "What we know from well established science and research is that there is no amount of talk or pressure that can make a gay person not gay, or a trans person not transgender," Levi said. "It's really important that licensed therapists don't abuse their position of trust to push an agenda that research has shown puts kids at high risk of suicide attempts and self harm." Levi said it is "always hard to anticipate the scope of the court's decision," but it is possible the ruling could have "quite significant" implications for other states that have banned the practice. Do Americans Support Conversion Therapy? A majority of Americans are opposed to conversion therapy, according to a poll from Data for Progress, which surveyed 1,155 likely voters from June 6 to June 8, 2025. Fifty-six percent of respondents said they agreed conversion therapy should be banned, while only 35 percent said they should be allowed to take place. Sixty-two percent of Democrats, 57 percent of independents and 49 percent of Republicans believed the practice should be banned. A December 2023 report from The Trevor Project found that there were 1,320 conversion therapy practitioners operating across the country, 605 of whom were operating under professional licenses. What Have Supreme Court Justices Said About Conversion Therapy? So far, at least one justice has signaled opposition to conversion therapy bans. After the court rejected a similar case out of Washington, conservative Justice Clarence Thomas dissented, writing, "There is a fierce public debate over how best to help minors with gender dysphoria. The petitioner, Brian Tingley, stands on one side of the divide. He believes that a person's sex is 'a gift from God, integral to our very being.'" Still, the court in 2023 rejected the challenge to a Washington law prohibiting conversion therapy. The Ninth Circuit Court of Appeals previously ruled that the law was regulating mental health care, not the speech of the provider. The court's decision to reject that challenge left that ruling in place. In addition to Thomas, Justices Samuel Alito and Brett Kavanaugh dissented from the rejection and would have heard the case. What People Are Saying Casey Pick, director of Law and Policy at The Trevor Project, told Newsweek: "The law at the heart of this case protects young people in Colorado from dangerous, discredited practices that have been proven to cause harm and increase suicide risk. This common-sense, bipartisan state law was put in place to prevent licensed mental health professionals from using these abusive practices on Colorado's youth; it really is that simple. "This law is squarely focused on ensuring that providers with government-issued licenses do not abuse the trust placed in them to subject minors to practices that have been rejected by every medical and mental health association in the country. We know that proponents of so-called conversion 'therapy' are making every attempt to impose an ideologically driven agenda. However, we remain hopeful that the justices will side with reason, evidence, and expertise, and uphold this effort by Colorado lawmakers to protect the health and safety of young people." Jonathan Scruggs, senior counsel and vice president of litigation strategy at the Alliance Defending Freedom, told Newsweek: "All who choose to live consistent with their biological sex are entitled to the help of counselors like Kaley as they work through that process. We hope the US Supreme Court will rule on the side of free speech and allow counselors like Kaley to work with her clients without the government mandating goals it prefers." Colorado Attorney General Phil Weiser, a Democrat, wrote in a statement in January: "In Colorado, we are committed to protecting professional standards of care so that no one suffers unscientific and harmful so-called gay conversion therapy. Colorado's judgment on this is the humane, smart, and appropriate policy and we're committed to defending." What Happens Next Oral arguments are set for October 7. The court has also been asked to weigh in on another major LGBTQ+ rights case. Kim Davis, the Kentucky clerk who refused to provide marriage licenses to same-sex couples after the legalization of same-sex marriage in 2015, has asked the court to revisit that ruling and overturn the national right to same-sex marriage. Legal experts told Newsweek that the case is a long shot, however.
Newsweek
2 hours ago
- Newsweek
Woman Desperate for Diagnosis for Years—Then Notices Ear Looks Different
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. For a decade, Holli Barron went in and out of doctor's offices, desperate for answers to a growing list of mysterious symptoms—throat swelling, rashes, extreme fatigue, and more. Despite receiving multiple diagnoses over the years, no treatment brought relief, leaving her feeling as if she was locked in a battle she couldn't win. That changed recently when she developed a new and unusual symptom: red, hot ear cartilage. It led to the correct diagnosis—relapsing polychondritis—a rare condition that causes repeated episodes of swelling and inflammation in cartilage and other tissues throughout the body, affecting fewer than 5,000 people in the U.S. Barron shared her experience in a TikTok video (@therapyandthings) that has been viewed over 526,000 times. She wrote: "When you send your rheumatologist a photo of 1 new weird symptom and suddenly after YEARS of no diagnosis you're getting seen by two specialists." She added that she underwent multiple tests and two CT scans in just 48 hours. "Living with a rare autoimmune disease also takes an emotional toll," the South Carolina mom told Newsweek. "Going years without a diagnosis can be difficult," Barron added, stressing the importance of caring for the mind, body, and soul, while navigating chronic illness. Two screenshots from the viral video showing Holli Barron looking puzzled and shocked. Two screenshots from the viral video showing Holli Barron looking puzzled and shocked. TikTok/@therapyandthings Sharing Her Story Online The licensed mental-health counselor later posted another video featuring photos of her ears. She warned viewers not to panic if they experience redness, as it was just one of many symptoms she had. "Prior to the ear redness and pain," Barron said, "including inflammatory arthritis, Raynaud's Phenomenon, tinnitus, episodes of minor vertigo, extreme fatigue, sensation of throat swelling, pain on the bridge of my nose. "Following CT scans, it was determined that I also have calcifications in the cartilage of my trachea," she added. The cartilage of Barron's ear is red and the lobe is the usual color. The cartilage of Barron's ear is red and the lobe is the usual color. Holli Barron Understanding Relapsing Polychondritis The Genetic and Rare Diseases (GARD) Information Center says relapsing polychondritis (RP) can also affect the airways (trachea), rib cartilage, eyes, heart, blood vessels, skin, kidneys, and nervous system. Signs and symptoms vary widely between individuals, depending on the areas involved. The exact cause is unknown, though both genetic influences and unidentified factors are believed to play a role. RP often occurs alongside autoimmune disorders. "Autoimmune disease symptoms can tend to overlap," Barron said. "So I don't want to say I was 'misdiagnosed,' but it did take many years to land at this correct diagnosis. Some previous diagnoses I was told included seronegative rheumatoid arthritis, lupus-like illness, tendinitis, and inflammatory arthritis." Living with an autoimmune disease while juggling mom life, a Ph.D., and work can be "challenging," Barron said—especially during flare-ups. "The fatigue and pain can be debilitating at times, making everyday tasks more difficult to complete," she added. How Is Relapsing Polychondritis Treated? Since only around 5 percent of rare diseases have FDA-approved treatments, finding a health-care team that can effectively manage symptoms and overall well-being is critical. People with rare diseases often face delayed diagnoses, limited treatment options, and difficulty finding providers with the necessary expertise. Building a care team that understands the patient's needs can greatly improve quality of life. For now, Barron will continue taking hydroxychloroquine, a disease-modifying antirheumatic drug (DMARD) that can reduce the pain of arthritis and swelling and prevent joint damage. "I will also be adding an immunosuppressant medication called Enbrel to hopefully slow the progression of the disease," Barron said. Is there a health issue that's worrying you? Let us know via health@ We can ask experts for advice, and your story could be featured on Newsweek.
